Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis
- PMID: 24829369
- DOI: 10.1136/heartjnl-2013-305187
Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis
Abstract
Background: Gadolinium-enhanced cardiovascular magnetic resonance is an emerging tool for the diagnosis of cardiac sarcoidosis (CS); however, the correlations between extent of late gadolinium enhancement (LGE) and efficacy of steroid therapy and adverse outcomes in patients with CS remain unclear.
Objective: We aimed to clarify the prognostic impact of extent of LGE in patients with CS.
Methods: Before the start of steroid therapy, 43 consecutive LGE-positive patients with CS were divided into two groups based on the extent of LGE by a median value: small-extent LGE (LGE mass <20% of LV mass; n=21) and large-extent LGE (LGE mass ≥20% of LV mass; n=22). We examined the correlations between extent of LGE and outcomes after steroid therapy.
Results: Among the 6 patients who died from heart disorders, 11 patients who were hospitalised because of heart failure and 6 patients who suffered life-threatening arrhythmia during the follow-up period, large-extent LGE predicted higher incidences of cardiac mortality and hospitalisation for heart failure. Multivariate Cox regression analysis showed that large-extent LGE was independently associated with combined adverse outcomes including cardiac death, hospitalisation for heart failure, and life-threatening arrhythmias. In the small-extent LGE group, LV end-diastolic volume index significantly decreased and LVEF significantly increased after steroid therapy, whereas in the large-extent LGE group, neither LV volume nor LVEF changed substantially.
Conclusions: Large-extent LGE correlates with absence of LV functional improvement and high incidence of adverse outcomes in patients with CS after steroid therapy.
Keywords: Myocardial Disease.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Similar articles
-
CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis.JACC Cardiovasc Imaging. 2013 Apr;6(4):501-11. doi: 10.1016/j.jcmg.2012.10.021. Epub 2013 Mar 14. JACC Cardiovasc Imaging. 2013. PMID: 23498675
-
Late gadolinium enhancement in cardiac sarcoidosis: characteristic magnetic resonance findings and relationship with left ventricular function.J Thorac Imaging. 2013 Jan;28(1):60-6. doi: 10.1097/RTI.0b013e3182761830. J Thorac Imaging. 2013. PMID: 23249970
-
Myocardial fibrosis as a key determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy: a contrast-enhanced cardiovascular magnetic study.Circ Cardiovasc Imaging. 2013 Sep;6(5):790-9. doi: 10.1161/CIRCIMAGING.113.000438. Epub 2013 Aug 9. Circ Cardiovasc Imaging. 2013. PMID: 23934992
-
Prognostic Value of Late Gadolinium Enhancement Detected on Cardiac Magnetic Resonance in Cardiac Sarcoidosis.JACC Cardiovasc Imaging. 2023 Mar;16(3):345-357. doi: 10.1016/j.jcmg.2022.10.018. Epub 2023 Jan 11. JACC Cardiovasc Imaging. 2023. PMID: 36752432
-
The pivotal role of cardiovascular imaging in the identification and risk stratification of non-compaction cardiomyopathy patients.Heart Fail Rev. 2020 Nov;25(6):1007-1015. doi: 10.1007/s10741-019-09898-8. Heart Fail Rev. 2020. PMID: 31784859 Review.
Cited by
-
Prognostic value of multimodality imaging in the contemporary management of cardiac sarcoidosis.Open Heart. 2024 Oct 27;11(2):e002989. doi: 10.1136/openhrt-2024-002989. Open Heart. 2024. PMID: 39462525 Free PMC article.
-
Cardiovascular Magnetic Resonance Imaging Patterns in Rare Cardiovascular Diseases.J Clin Med. 2022 Oct 29;11(21):6403. doi: 10.3390/jcm11216403. J Clin Med. 2022. PMID: 36362632 Free PMC article. Review.
-
Sarcoid heart disease and imaging.Heart Rhythm O2. 2023 Nov 19;5(1):50-59. doi: 10.1016/j.hroo.2023.11.012. eCollection 2024 Jan. Heart Rhythm O2. 2023. PMID: 38312203 Free PMC article. Review.
-
Assessment of the 2017 AHA/ACC/HRS Guideline Recommendations for Implantable Cardioverter-Defibrillator Implantation in Cardiac Sarcoidosis.Circ Arrhythm Electrophysiol. 2019 Sep;12(9):e007488. doi: 10.1161/CIRCEP.119.007488. Epub 2019 Aug 21. Circ Arrhythm Electrophysiol. 2019. PMID: 31431050 Free PMC article.
-
Routine Laboratory Biomarkers As Prognostic Indicators of Cardiac Sarcoidosis Outcomes.Sarcoidosis Vasc Diffuse Lung Dis. 2022;39(3):e2022023. doi: 10.36141/svdld.v39i2.11136. Epub 2022 Sep 23. Sarcoidosis Vasc Diffuse Lung Dis. 2022. PMID: 36791034 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical